JP2017508442A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508442A5
JP2017508442A5 JP2016546862A JP2016546862A JP2017508442A5 JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5 JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5
Authority
JP
Japan
Prior art keywords
genes listed
derivative
mdm2i
salt
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/051157 external-priority patent/WO2015108175A1/en
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

JP2016546862A 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A JP2017508442A (ja) 2017-03-30
JP2017508442A5 true JP2017508442A5 (OSRAM) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (OSRAM)
EP (1) EP3094746A1 (OSRAM)
JP (1) JP2017508442A (OSRAM)
WO (1) WO2015108175A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3197477A4 (en) 2014-09-24 2018-07-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
TWI806822B (zh) * 2015-10-23 2023-07-01 日商第一三共股份有限公司 製備治療癌症之醫藥組成物之用途
CN108135884A (zh) * 2015-10-23 2018-06-08 第三共株式会社 用于治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US20220249538A1 (en) * 2019-05-23 2022-08-11 Osaka University Treatment agent for sex hormone-insensitive greb1-positive tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371568B2 (en) * 2012-07-31 2016-06-21 Novartis Ag Markers associated with human double minute 2 inhibitors
KR101879926B1 (ko) * 2013-07-03 2018-08-16 에프. 호프만-라 로슈 아게 MDM2 길항제를 사용한 환자 암 치료를 개인화하기 위한 mRNA-기반 유전자 발현

Similar Documents

Publication Publication Date Title
JP2017508442A5 (OSRAM)
Degtyareva et al. Regulatory SNPs: altered transcription factor binding sites implicated in complex traits and diseases
Schlauch et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome
Desai et al. Next‐generation sequencing: ready for the clinics?
ES2577289T3 (es) Calreticulina mutante para el diagnóstico de malignidades mieloides
Bonnefond et al. Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing
EP4574992A3 (en) Combinatorial dna screening
Lin et al. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing
CN112930569A (zh) 无细胞dna中的微卫星不稳定性检测
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
Maes et al. Beyond H&E: Integration of nucleic acid–based analyses into diagnostic pathology
Vasli et al. Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders
JP2017512491A5 (OSRAM)
JP2016000057A5 (OSRAM)
JP2012501452A5 (OSRAM)
WO2021046466A1 (en) Methods, compositions, and systems for profiling or predicting an immune response
JP2017532959A5 (OSRAM)
JP2011528903A5 (OSRAM)
JP2017509351A5 (OSRAM)
Caberlotto et al. Systems biology meets-omic technologies: novel approaches to biomarker discovery and companion diagnostic development
WO2016141044A1 (en) Erbb4 inhibitors and methods of use thereof
RU2009127735A (ru) Определение предрасположенности к раку путем идентификации генотипических комбинаций специфичных вариантов генов cyp1b1, brca2 и снек2
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
JP2012507291A5 (OSRAM)